Coegin Pharma (FRA:7Z6) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 12, 2026)


FRA:7Z6 Coegin Pharma FRA:7Z6
38 GF Score
Price €0.28
! 2 Warning Signs
View Full Analysis

What is Coegin Pharma Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Coegin Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:7Z6 vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Coegin Pharma's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coegin Pharma Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coegin Pharma's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Coegin Pharma's Margin of Safety % (DCF FCF Based) falls into.


FRA:7Z6
38GF Score
Coegin Pharma FRA:7Z6
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coegin Pharma Business Description

Other Exchanges COEGIN:Sweden
Address c/o Medicon Village, Lund, SWE, 223 81
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
38GF Score

Get the complete analysis for FRA:7Z6

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.28
Price